文献速递消化、代谢与肾脏急症

芬兰三十年间上、下消化道出血的发病率与死亡率趋势

Thirty-Year Incidence and Mortality Trends in Upper and Lower Gastrointestinal Bleeding in Finland.
PubMed 文献 · JAMA Netw Open · 2020-10-01
一句话结论一般人群中下消化道出血发病率高于上消化道出血,但上消化道出血的复发率、死亡率和28天病死率更高。

上消化道出血年龄标化发病率为0.94/1000人年(95%CI 0.85-1.04),下消化道出血为1.26/1000人年(95%CI 1.15-1.38),男性高于女性。上消化道出血特异性死亡率0.07/1000人年(95%CI 0.04-0.09)高于下消化道出血的0.01/1000人年(95%CI 0.001-0.03)。上消化道出血28天病死率7.0%(95%CI 4.7-10.1)高于下消化道出血的0.4%(95%CI 0.1-1.3),男性病死率(5%-10%)高于女性(<2%)。

要点

  • 上消化道出血年龄标化发病率0.94/1000人年(95%CI 0.85-1.04),下消化道出血1.26/1000人年(95%CI 1.15-1.38),下消化道出血发病率更高。
  • 上消化道出血28天病死率7.0%(95%CI 4.7-10.1),显著高于下消化道出血的0.4%(95%CI 0.1-1.3)。
  • 上消化道出血特异性死亡率0.07/1000人年(95%CI 0.04-0.09),高于下消化道出血的0.01/1000人年(95%CI 0.001-0.03)。
  • 1987至2016年间上消化道出血发病率基本稳定(0.40-0.66/1000人年),下消化道出血发病率持续上升后趋于稳定。
  • 消化道出血复发事件比例在1987至2016年间呈上升趋势;男性病死率(5%-10%)高于女性(<2%)。

适用人群与场景

  • 芬兰FINRISK研究1987至2012年各周期纳入的25-74岁成年人,从人群登记处随机抽样招募,排除有消化道出血住院史者。
  • 随访从入组至因消化道出血住院、全因死亡或研究结束(2016年12月31日)。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 上消化道出血494例(1.3%),下消化道出血645例(1.7%)。
  • 上消化道出血年龄标化发病率0.94/1000人年(95%CI 0.85-1.04),下消化道出血1.26/1000人年(95%CI 1.15-1.38),男性高于女性。
  • 1987至2016年上消化道出血发病率基本稳定(0.40-0.66/1000人年),下消化道出血发病率持续上升后趋于稳定;复发事件比例呈上升趋势。
  • 上消化道出血特异性死亡率0.07/1000人年(95%CI 0.04-0.09)高于下消化道出血的0.01/1000人年(95%CI 0.001-0.03)。
  • 上消化道出血28天病死率7.0%(95%CI 4.7-10.1),下消化道出血0.4%(95%CI 0.1-1.3);男性病死率5%-10%,女性<2%。

证据类型、等级与局限

  • 证据类型为前瞻性队列研究。
  • 原文未述证据等级或推荐强度。
  • 原文未述局限性。

对床旁实践的改变

  • 原文指出这些数据可作为参照,用于解读药物相关消化道出血的发生率,并可为改善消化道出血诊治、预防再出血或死亡提供信息。

指南或共识出处

  • JAMA Network Open

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Epidemiological data on lower gastrointestinal bleeding (GIB) in the general population are sparse.

OBJECTIVE: To describe the incidence, recurrence, mortality, and case fatality rates of major upper GIB and lower GIB in the general population of Finland between 1987 and 2016.

DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study used data from the 1987 to the 2012 cycles of the National FINRISK Study, a health examination survey that was conducted every 5 years in Finland. Survey participants were adults aged 25 to 74 years who were recruited from a population register by random sampling; those with a history of hospitalization for GIB were excluded. Participants were followed up from survey enrollment to onset of GIB that led to hospitalization, death from any cause, or study end (December 31, 2016). Follow-up was performed through linkage with national electronic health registers. Data were analyzed from February 1, 2019, to January 31, 2020.

MAIN OUTCOMES AND MEASURES: Incidence, recurrence, mortality, and case fatality rates for all, upper, lower, and unspecified GIB. Outcome measures were stratified by sex and age group.

RESULTS: Among the 39 054 participants included in the study, 494 (1.3%) experienced upper GIB (321 men [65.0%]; mean [SD] age, 52.8 [12.1] years) and 645 (1.7%) had lower GIB (371 men [57.5%]; mean [SD] age, 54.0 [11.7] years). The age-standardized incidence rate was 0.94 per 1000 person-years (95% CI, 0.85-1.04) for upper GIB and 1.26 per 1000 person-years (95% CI, 1.15-1.38) for lower GIB; the incidence was higher in men than in women. Between 1987 and 2016 the incidence rate of upper GIB remained mostly stable, ranging from 0.40 to 0.66 per 1000 person-years, whereas constant increases occurred in the incidence of lower GIB until the rate stabilized. The proportion of recurrent GIB events showed an increasing trend from 1987 to 2016. The upper GIB-specific mortality was higher (0.07 per 1000 person-years; 95% CI, 0.04-0.09) than the lower GIB-specific mortality (0.01 per 1000 person-years; 95% CI, 0.001-0.03). Case fatality was high for those with upper GIB (7.0%; 95% CI, 4.7-10.1) compared with those with lower GIB (0.4%; 95% CI, 0.1-1.3). Case fatality remained stable over the years but was higher in men (between 5% and 10%) than women (<2%) with GIB.

CONCLUSIONS AND RELEVANCE: This study found that the overall incidence rate of upper GIB was lower than the incidence of lower GIB, but the recurrence, mortality, and 28-day case fatality were higher in participants with upper GIB. These data can serve as a reference when putting into context the rates of drug-associated GIB and can inform efforts to improve GIB care and outcome and to prevent rebleeding or death for patients with major GIB.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Vora P, Pietila A, Peltonen M, et al. Thirty-Year Incidence and Mortality Trends in Upper and Lower Gastrointestinal Bleeding in Finland. JAMA Netw Open. 2020. PMID: 33034641. doi:10.1001/jamanetworkopen.2020.20172

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。